Sulodexide and chronic kidney disease: clinical and experimental studies


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Clinical and experimental studies, demonstrating antialbuminuric effects of sulodexide, are discussed.

全文:

受限制的访问

作者简介

A. Svistunov

V. Fomin

参考

  1. Nikkila E., Grasbeck R. Heparin in lipoid nephrosis: observations of the effects on edema, proteinuria, serum proteins, lipids and lipoproteins. Acta Med Scand. 1954; 150(1): 39-46.
  2. Poplawski A. Effect of heparin on proteinuria and other biochemical parameters in nephrotic syndrome. Pol Tyg Lek. 1974;29(10):289-291.
  3. Кутырина И.М., Никишова Т.В., Тареева И.Е. Гипотензивное и диуретическое действие гепарина у больных хроническим гломерулонефритом. Тер. арх. 1985; 6: 78-81.
  4. Mandal A.K., Lyden T.W., Saklaen M.G. Heparin lowers blood pressure. Kidney Int. 1995; 47:1017-1022.
  5. Козловская Н.Л. Низкомолекулярные гепарины в практике нефролога. Клин. нефрология. 2011; 1:15-22.
  6. Козловская Н.Л., Шилов Е.М., Шахнова Е.А. и др. Низкомолекулярные гепарины в лечении АФС-нефропатии при первичном и вторичном антифосфолипидном синдроме. Тер. арх. 2004; 9:35-40.
  7. Gambaro G., Baggio B. Glycosaminoglicans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol. Dial. Transplant. 1996; 11: 762-764.
  8. Benck U., Haeckel S., Clorius J.H. et al. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system. Clin J Am Soc Nephrol. 2007; 2(1): 58-67.
  9. Harvey S.J., Miner J.H. Revisiting the glomerular charge barrier in the molecular era. Curr Opin Nephrol Hypertens. 2008; 17: 393-398.
  10. van der Born J., van del Havuel L., Bakker M. et al. Distribution of GBM heparin sulphate proteoglycan core protein and side chanins in human glomerular disease. Kidney Int. 1993;43: 454-463.
  11. Tamsma J., van der Born J., Bruijn J. et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparin sulphate in the glomerular basal membrane. Diabetologia. 1994;37:313-320.
  12. Raats C., Luca M., Bakker M. et al. Reduction in glomerular heparin sulphate correlates with complement deposition and albuminuria in active Heymann nephritis. J Am Soc Nephrol. 1999; 10:1689-1699.
  13. Pillarisetti S. Lipoprotein modulation of seubendothelial heparin sulphate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med. 2000; 10: 60-65.
  14. van der Hoven M.J., Rops A.L., Vladovsky I. et al. Heparanase in glomerular diseases. Kidney Int. 2007;72:543-548.
  15. Lewis E.J., Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy, implications for the therapeutic use of low-molecular weight heparin. Diabetes Care. 2008;31(Suppl. 2): S202-S207.
  16. Wijnhoven T.J., van den Hoven M.J., Ding H. et al. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia 2008;51:372-382.
  17. Jensen T. Pathogenesis of diabetic vascular disease, evidence for the role of reduced heparin sulphate proteoglycan. Diabetes. 1997; 46 (Suppl. 2): S98-S100.
  18. Wijnhoven T.J., Lensen J.F., Rops A.L. et al. Anti-proteinuric effects of glycosaminoglycan-based drugs. Curr Opin Mol Ther. 2007;9:364-377.
  19. Ruggeri A., Guizzardi S., Franchi M. et al. Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II: Organ distribution in rats. Arzneimittelforschung. 1985; 35:1517-1519.
  20. Karon J., Polubinska A., Antoniewicz A.A. et al. Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif. 2007; 25: 510-514.
  21. Ciszewicz M., Polubinska A., Antoniewicz A. t al. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res. 2009; 153: 118-123.
  22. Kristova V., Liskova S., Sotnikova R. et al. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res. 2008;57:491-494.
  23. Rossini M., Naito T., Yang H. et al. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant. 2010; 25(6):1803-1810.
  24. Yung S., Chau M.K., Zhang Q. et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One. 2013;8(1):e54501.
  25. Jin H.Y., Lee K.A., Song S.K. et al. Sulodexide prevents peripheral nerve damage in streptozocin induced diabetic rats. Eur J Pharmacol. 2012; 674(2-3): 217-226.
  26. Li P., Ma L.L., Xie R.J. et al. Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure. Acta Pharmacol Sin. 2012; 33(5): 644-651.
  27. Solini A., Vergnani L., Ricci F. et al. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care. 1997; 20(5): 819-823.
  28. Sorrenti G., Grimaldi M., Canova N. et al. Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients. A pilot study. J Int Med Res. 1997; 25(2): 81-86.
  29. Skrha J., Perusicova J., Pontuch P. et al. Gycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract. 1997;38(1): 25-31.
  30. Шестакова М.В., Чугунова Л.А., Воронцов А.В. и др. Эффективность сулодексида - низкомолекулярного гепарина - в терапии диабетической нефропатии. Тер. арх. 1997;6:34-37.
  31. Gambaro G., Kinalska I., Oksa A. et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002; 13(6): 1615-1625.
  32. Achour A., Kacem M., Dibej K. et al. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2005; 18(5):568-574.
  33. Sulikowska B., Olejniczak H., Muszynska M. et al. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol. 2006; 26(6): 621-628.
  34. Heerspink H.L., Greene T., Lewis J.B. et al.; Collaborative Study Group. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant. 2008;23(6):1946-1954.
  35. Packham D.K., Wolfe R., Reutens A.T. et al.; Collaborative Study Group. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23(1): 123-130.
  36. Lewis E.J., Lewis J.B., Greene T. et al.; Collaborative Study Group. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011; 58(5): 729-736.
  37. House A.A., Weir M.A. Sulodexide for diabetic nephropathy: another one bites the dust. Am J Kidney Dis. 2011; 58(5): 692-694.
  38. Blouza S., Dakhli S., Abid H. et al.; DAVET (Diabetic Albuminuria Vessel Tunisia Study Investigators). Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2010; 23(4): 415-424.
  39. Masola V., Onisto M., Zaza G. et al. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transi Med. 2012; 10: 213.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##